| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/TP.0B013E31829434D4 |
| P698 | PubMed publication ID | 23632391 |
| P50 | author | Ole Øyen | Q37830274 |
| Christian Naper | Q59159800 | ||
| Erik G. Ström | Q59296777 | ||
| Hallvard Holdaas | Q88676506 | ||
| Anders Hartmann | Q89348476 | ||
| Karsten Midtvedt | Q96205673 | ||
| Trond Jenssen | Q98904299 | ||
| Christina Dörje | Q114301035 | ||
| Torbjørn Leivestad | Q114301041 | ||
| Jørn Petter Lindahl | Q114301044 | ||
| P2093 | author name string | Anna Varberg Reisæter | |
| Tommy Aronsen | |||
| Linda Flaa-Johnsen | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 79-84 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Early versus late acute antibody-mediated rejection in renal transplant recipients | |
| P478 | volume | 96 |
| Q41118002 | Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management |
| Q41358191 | Acute Rejection in Renal Transplant Patients of a Hospital in Bogota, Colombia |
| Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
| Q41495990 | Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection |
| Q36822826 | Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients. |
| Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
| Q104802057 | Clinical and Pathologic Feature of Patients With Early Versus Late Active Antibody-Mediated Rejection After Kidney Transplantation: A Single-Center Experience |
| Q47147931 | Clinical risk stratification of paediatric renal transplant recipients using C1q and C3d fixing of de novo donor-specific antibodies |
| Q38795065 | Current pathological perspectives on chronic rejection in renal allografts |
| Q39801687 | Donor-specific antibodies present at the time of kidney transplantation in immunologically unmodified patients increase the risk of acute rejection. |
| Q47286616 | Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. |
| Q36887183 | Expanding the antibody-mediated component of plasma cell-rich acute rejection: A case series |
| Q92803495 | How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection? |
| Q51591178 | Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney. |
| Q38429887 | Identifying endpoints to predict the influence of immunosuppression on long-term kidney graft survival |
| Q47409507 | Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant |
| Q37660263 | Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy |
| Q27006030 | Late and chronic antibody-mediated rejection: main barrier to long term graft survival |
| Q40149564 | Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. |
| Q35565364 | One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts |
| Q64899061 | Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation. |
| Q38699017 | Tacrolimus and mycophenolate regimen and subclinical tubulo-interstitial inflammation in low immunological risk renal transplants. |
| Q26774993 | The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients |
| Q38258153 | The increasing clinical importance of alloantibodies in kidney transplantation |
| Q38370826 | The need for minimization strategies: current problems of immunosuppression. |
| Q48162490 | The time dependency of renal allograft histology |
| Q53117621 | Total inflammation in early protocol kidney graft biopsies does not predict progression of fibrosis at one year post-transplant. |
| Q42102593 | Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center. |
| Q28069336 | Unraveling the Role of Allo-Antibodies and Transplant Injury |
| Q35790601 | Utility of HLA Antibody Testing in Kidney Transplantation |
| Q38818479 | mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now? |
Search more.